Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?



Anti-Cancer Agents in Medicinal Chemistry, 12(2): 137-143.

Author(s): Vera Hirsh.

Affiliation: Departments of Medicine and Oncology, McGill University Health Centre, Royal Victoria Hospital, Room A2.04, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada.

Abstract

Bisphosphonates are the current standard of care for patients with bone metastases from advanced solid tumors. Zoledronic acid has demonstrated the broadest activity in this setting, and is approved for the prevention of skeletal-related events from bone metastases from a variety of solid tumors in addition to breast cancer and multiple myeloma. Ongoing studies are evaluating the antiresorptive potentials of investigational agents in these settings. A large body of preclinical evidence and recent clinical developments support the hypothesis that zoledronic acid can exert clinically meaningful anticancer activities in some settings, thereby improving disease outcomes and survival. These data are especially strong in breast cancer and multiple myeloma, and are emerging in other cancer settings. This review article will discuss the emerging data suggesting an anticancer role for bisphosphonates in the context of lung cancer and solid tumors other than breast and genitourinary malignancies.

Keywords:

Bone metastases, Non-small cell lung cancer, Skeletal-related events, Zoledronic acid, Bone markers, Survival, Skeletal Morbidity, NTX levels, ZOL infusion.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 12
Issue Number: 2
First Page: 137
Last Page: 143
Page Count: 7
DOI: 10.2174/187152012799014922
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science